Enzalutamide in treatment in patients with metastatic castration‑resistant prostate cancer after previous chemotherapy

03/2017

MUDr. Igor Richter, Ph.D.^1,2, doc. MUDr. Josef Dvořák, Ph.D.², MUDr. Věra Hejzlarová¹, MUDr. Jiří Bartoš, MBA¹

1. Komplexní onkologické centrum, Krajská nemocnice Liberec, a.s.

2. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

SUMMARY

Introduction: The aim of this retrospective study is demonstrated efficacy and tolerance of enzalutamide therapy in real clinical practice in 33 patients with metastatic castration-resistant prostate cancer (mCRPC) who had previous chemotherapy.

Patients and methods: Between November 2014 and June 2016 we treated with enzalutamide a total of 33 patients with metastatic castrate resistant prostate cancer. The all patients were previous treated by one or two lines of chemotherapy. The enzalutamide was administered by standard dose 160 mg daily.

Results: One patient had cerebral hemorrhage grade IV. In other patients the non-hematological toxicity evaluation did not achieve the grade III or IV. Anemia grade III-IV was described in 6 patients and thrombocytopenia grade III-IV in 2 patients. The median of progression free survival was 7.0 (95% CI 6.1-7.9) months. The median of overal survival was 8.4 (95 % CI 5.1-11.7) months.

Conclusion: The study demonstrated our first experience with enzalutamid in postchemo-indication in patients with mCRPC with good toleration and efficacy.

KEY WORDS

prostate cancer, metastases, androgen receptor, overal survival, progression free survival, toxicity